This document discusses Medicortex's solution for rapid and accurate detection of traumatic brain injuries (TBI). It describes the need for improved TBI diagnostics given millions of new TBI cases annually. Medicortex has developed a biomarker test kit that can be used at the point-of-injury to detect TBI biomarkers in saliva or urine. The document outlines Medicortex's research and clinical trials, which have shown the test kit can successfully detect biomarkers that indicate TBI. It then discusses the kit's advantages, potential clients and large market opportunity. Finally, it provides details on Medicortex's intellectual property, financing history, leadership team and future development plans.

1. Traumatic Brain Injury
Complex problem – Creative solution
December 2021
©

2. Introduction to the
TBI Problem and Our Solution

3. •
•
•
•
•
• The Need: Accurate and rapid detection
of head injuries
Traumatic Brain Injury (TBI)

4. 48 %
17 %
13 %
8 %
14 % Falls
Assault
Motor vehicle
accidents Being struck by or
against an object
Leading Causes of TBI
Other or unknown
cause
Blasts and explosions,
Firearms, Diving, Medical
Procedures

5. TBI – A Global Problem
•
•
•
•
•
New cases each year
90% of cases are mild traumatic brain
injuries
•

6. Our Solution for Diagnostics
A B

7. Easy-to-read

8. Why is the kit needed?
•
•
•

9. • biomarker
test
•
•

10. Research and Development
Performed and Planned

11. Preclinical results indicated the existence of
unique biomarkers following a head injury
Control animals (no injury)
Head injured animals
Biomarker elevation after injury
(fluoresent detection)
Intensity
increase
(2
parallel
spots/biomarker)

12. Clinical trials
24
16
29
12
12
•
•
•
•
Completed

13. 28
30
Binding analysis
Biomarker detection
Mass spectrometry
Glycome analysis
3D-structure
2020-Q2 2021-Q2

14. Clinical Trials – Conclusions
•
•
•
• Medicortex reached a significant milestone
Analysis of the samples
from the clinical study with
children is supported by
Business Finland.

15. 2nd Clinical Study Summary
Saliva Urine

16. Biomarker detection on a strip
Visual outlook Measured darkness of spots

17. A case study – T
estimonial
•
•
•
•
•
•
•

18. Biomarker results

19. The case study – second MRI
MRI scanning was repeated after the biomarker results
•
•

20. From an Idea to the Product
Clinical evaluation of the final product

21. Financial and Development Milestones
PHASE
PRE-
CLINICAL
STUDIES
FIRST CLINICAL
STUDY
SECOND
CLINICAL STUDY
PEDIATRIC
CLINICAL STUDY
PROTOTYPE
DEVELOPMENT
VALIDATION
AND
APPROVAL
TASKS
™
™
MILESTONES
FUNDING
NEEDED
(M€)*
 2.5  2.5
STATUS

22. ProbTBI™ Kit advantages
Fast Easy to use
Mobility Patient friendly
No radiation or
contrast agent
exposition
Affordable
Can be sold as
"off the shelf" product
ProbTBI™
Kit

23. Our Potential Clients
Army
paramedics
Hospitals and
emergency rooms
Paramedics First
responders
Sport
teams
Nursing
homes
Insurance
companies
Pharma
companies
Private
people

24. Market Potential

25. Drug development

26. Neuro-protective Medication for
Brain Injury
•
•
•
•
•
•
•

27. Neuro-protective Medication for
Brain Injury

28. New chemical entities (NCE)
YR1/Q1 YR1/Q2 YR1/Q3 YR1/Q4 YR2/Q1 YR2/Q2 YR2/Q3 YR2/Q4 YR 3 YR 4 YR 5
Synthesis
Physico-chemical characterization
Kinetic solubility and stability testing
Ex-vivo testing for plasma half-life
In-vitro functionality testing
Testing of metal ion binding capabilities
Testing of anti-oxidative capacity
In-vitro toxicity
Ex-vivo efficacy testing
In-vitro evaluation of BBB penetration capabilities
In-vitro proof of concept/efficacy
Ex-vivo brain tissue evaluation
In-vivo efficacy and pharmacology testing
In-vivo therapeutic index estimation/efficacy
In-vivo toxicology: dose escalation and MTD
Regulatory application
Detailed R&D Roadmap For Drug
development

29. Intellectual Property
Position

30. Patents for the biomarker and diagnostics
1. Prognostic and Diagnostic Glycan-based Biomarkers of Brain
Damage
•
•
•
•
2. Non-invasive brain injury diagnostic device
•
•
3. Device and method for detecting of brain injury in a subject
•
4. A method for determining a lectin-binding glycan indicative to
traumatic brain injury
•

31. Patents for the drug development
Multivalent compounds for use in the treatment and prevention
of brain damage
•
•
•
•
Conjugates and conjugates for use in preventing or treating of
brain damage and neurodegenerative diseases
•
Patent for COVID-19 diagnostics
Method for determining coronavirus and kit for the same
•

32. Public and Private
Financing

33. Equity up to now
•
•
Pre-IPO share issue
•
•
•
Subsidies
•
•

34. Use of Funds 2022–2024
Near-future investments will be used
for diagnostic kit development:
•
•
•
•

35. From 2014-2021 increase in value
0
2
4
6
8
10
12
14
Valuation
(M€)
Price
per
Share
(€) Value Creation
Valuation (M€) Price per Share
Paediatric Clinical Trial
Prototype development
Q3/2014 Q3/2015 Q2/2016 Q4/2016 Q4/2017 Q4/2018 Q3/2019 Q3/2021
Funding from
Tekes and new
Investors
DoD
funding
Human Clinical
Trials in three
hospitals
First Human Clinical Trial
Positive clinical results
Crowdfunding
Positive
preclinical
results

36. Acquisitions and Buy-Outs
Some examples in the range of <60 M€
Target company / Acquired by:

37. Board of Directors
• Adrian Harel
• Mårten Kvist
• T
om Palenius

38. Scientific and Clinical Advisory Board
Timo Kurki
Antti Kaipia
Markku Tuominen
Heikki Rauvala
Lauri Kangas
Risto O. Roine

39. The T
eam
Adrian Harel
Mårten Kvist
Lasse Välimaa
Oskar Haavisto
Ivette Bañuelos
Laboratory Assistant
Venla-Mari Nurmi
Jesper Lindholm

40. Medicortex
in the Press
2
3
4
5
6
7
1

41. Concussion in sports and Medicortex test
Concussion in army personnel and Medicortex test

42. www.medicortex.fi
Contact:
Dr
. Adrian Harel, CEO
adrian.harel@medicortex.fi